TNNI3 and metabolic dysfunction-associated steatohepatitis: Meanwhile, treatment with BM-MSCs achieved significant decrease in serum CK-MB levels only by 18%, with non-significant decrease in serum levels of LDH and cTnI, as compared to cardiotoxicity induced by NASH group.